Humana's (HUM) targeted Medicare Advantage margin could be delayed to 2028, rather than 2027, given its Stars ratings miss last year, RBC Capital Markets said.
"We attribute much of Tuesday's intra-day weakness to a slight shift in narrative regarding
the path to Stars recovery and by extension the path to target 3% Medicare Advantage margin, which sounds incrementally more like a 2028 story," the investment firm said in a note Tuesday.
Humana's strategy to reach the 3% margin includes optimizing costs and achieving a normalized rate environment, which RBC noted would need to be stronger than what CMS initially proposed for 2026.
The company's management reiterated that they are focused on the 2025 measurement period, which would impact 2028 Stars, giving them a full-year runway for operational improvement.
The firm said it lowered its 2026 estimates for Humana due to its continued investment in clinical capabilities aimed at improving Stars ratings.
RBC maintained its outperform rating on Humana and its $283 price target.
Price: 262.14, Change: +4.80, Percent Change: +1.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。